$40.7M
+$40.7M this year1 filing since 2026 · latest Equity filed
Terremoto Biosciences is a clinical-stage biotechnology company in South San Francisco developing small-molecule medicines built on novel covalent chemistry. Its work centers on AKT1-selective inhibitors intended to engage the target inside tumor cells while sparing other AKT isoforms. The lead program, TER-2013, is in a Phase 1 trial in breast cancer and other solid tumors with PI3K/AKT/PTEN pathway alterations, and a second molecule, TER-4480, is in IND-enabling studies for hereditary hemorrhagic telangiectasia. The company closed a $108 million Series C in April 2026 to fund clinical development of both programs.
What sets it apart
Covalency technologies that make previously undruggable sites addressable, yielding isoform-selective AKT1 inhibitors that avoid the hyperglycemia and rash toxicities that limited earlier pan-AKT drugs and their narrow therapeutic windows.
An orally available, AKT1-selective small-molecule inhibitor in a Phase 1 clinical trial (NCT-07109726) for breast cancer and other solid tumors carrying PI3K/AKT/PTEN pathway alterations.
